Jonathan Golas
Overview
Explore the profile of Jonathan Golas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
592
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maresca K, Chen J, Mathur D, Giddabasappa A, Root A, Narula J, et al.
Mol Imaging Biol
. 2021 Jun;
23(6):941-951.
PMID: 34143379
Purpose: A sensitive and specific imaging biomarker to monitor immune activation and quantify pharmacodynamic responses would be useful for development of immunomodulating anti-cancer agents. PF-07062119 is a T cell engaging...
2.
Molina-Sanchez P, Ruiz de Galarreta M, Yao M, Lindblad K, Bresnahan E, Bitterman E, et al.
Gastroenterology
. 2020 Aug;
159(6):2203-2220.e14.
PMID: 32814112
Background And Aims: The pattern of genetic alterations in cancer driver genes in patients with hepatocellular carcinoma (HCC) is highly diverse, which partially explains the low efficacy of available therapies....
3.
Mathur D, Root A, Bugaj-Gaweda B, Bisulco S, Tan X, Fang W, et al.
Clin Cancer Res
. 2020 Jan;
26(9):2188-2202.
PMID: 31996389
Purpose: Gastrointestinal cancers remain areas of high unmet need despite advances in targeted and immunotherapies. Here, we demonstrate potent, tumor-selective efficacy with PF-07062119, a T-cell engaging CD3 bispecific targeting tumors...
4.
Ji C, Roy M, Golas J, Vitsky A, Ram S, Kumpf S, et al.
Clin Cancer Res
. 2019 May;
25(15):4735-4748.
PMID: 31085720
Purpose: Immune checkpoint inhibitors (ICI) targeting PD1, PDL1, or CTLA4 are associated with immune-related adverse events (irAE) in multiple organ systems including myocarditis. The pathogenesis and early diagnostic markers for...
5.
Fisher T, Hooper A, Lucas J, Clark T, Rohner A, Peano B, et al.
Cancer Immunol Immunother
. 2017 Oct;
67(2):247-259.
PMID: 29067496
Strong evidence exists supporting the important role T cells play in the immune response against tumors. Still, the ability to initiate tumor-specific immune responses remains a challenge. Recent clinical trials...
6.
Sung M, Tan X, Lu B, Golas J, Hosselet C, Wang F, et al.
Mol Cancer Ther
. 2017 Oct;
17(1):243-253.
PMID: 29054985
Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate (ADC) that has demonstrated clinical benefit for patients with HER2 metastatic breast cancer; however, its clinical activity is limited by inherent or acquired...
7.
Golas J, Lucas J, Etienne C, Golas J, Discafani C, Sridharan L, et al.
Cancer Res
. 2005 Jun;
65(12):5358-64.
PMID: 15958584
Src up-regulation is a common event in human cancers. In colorectal cancer, increased Src levels are an indicator of poor prognosis, and progression to metastatic disease is associated with substantial...
8.
Tsou H, Overbeek-Klumpers E, Hallett W, Reich M, Floyd M, Johnson B, et al.
J Med Chem
. 2005 Feb;
48(4):1107-31.
PMID: 15715478
A series of new 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitrile derivatives that function as irreversible inhibitors of human epidermal growth factor receptor-2 (HER-2) and epidermal growth factor receptor (EGFR) kinases have been prepared. These compounds...
9.
Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase
Rabindran S, Discafani C, Rosfjord E, Baxter M, Floyd M, Golas J, et al.
Cancer Res
. 2004 Jun;
64(11):3958-65.
PMID: 15173008
HER-2 belongs to the ErbB family of receptor tyrosine kinases, which has been implicated in a variety of cancers. Overexpression of HER-2 is seen in 25-30% of breast cancer patients...